OKI-219 dosed at 900 mg twice daily shows steady-state exposure levels with near-continuous coverage of the in vivo EC 80 for pAKT inhibition. These data are consistent with the Company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback